Sugi Predict

Sugi Predict / Targets / CYP2F1

CYP2F1

Cytochrome P450 2F1 (EC 1.14.14.1) (CYPIIF1) · P24903 · CYP2F1 on Sugi Atlas →

6,952 patent compounds predicted against CYP2F1, 4,509 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2753072 SCHEMBL2753072 0.56 3/20
SCHEMBL2752346 SCHEMBL2752346 0.52 3/20
SCHEMBL2752131 SCHEMBL2752131 0.52 3/20
SCHEMBL1165314 SCHEMBL1165314 0.47 3/20
SCHEMBL971260 SCHEMBL971260 0.42 3/20
SCHEMBL2749440 SCHEMBL2749440 0.42 3/20
SCHEMBL2752725 SCHEMBL2752725 0.41 3/20
SCHEMBL2091704 SCHEMBL2091704 0.41 3/20
SCHEMBL971261 SCHEMBL971261 0.40 3/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL2566375) 0.90 2/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL2592428) 0.90 2/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL2570005) 0.89 2/20
SCHEMBL2584612 SCHEMBL2584612 0.79 2/20
SCHEMBL2407878 SCHEMBL2407878 0.74 2/20
SCHEMBL196765 SCHEMBL196765 0.73 2/20
SCHEMBL2580241 SCHEMBL2580241 0.72 2/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL2592437) 0.70 2/20
SCHEMBL2582318 SCHEMBL2582318 0.68 2/20
SCHEMBL1180429 SCHEMBL1180429 0.67 2/20
SCHEMBL1181635 SCHEMBL1181635 0.67 2/20

Clinical trials — most relevant to CYP2F1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer PHASE1/PHASE2COMPLETED
Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer PHASE2COMPLETED
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma PHASE2NOT_YET_RECRUITING
A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer PHASE2ACTIVE_NOT_RECRUITING
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis PHASE2ACTIVE_NOT_RECRUITING
Endoxifen in Adults With Hormone Receptor Positive Solid Tumors PHASE1COMPLETED
Effect of Dexamethasone on CYP Enzyme Activity in Healthy Male Subjects PHASE1NOT_YET_RECRUITING
The Antibiotic Rifampin to Reduce High Levels of Blood and Urine Calcium in IIH PHASE1UNKNOWN
BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab PHASE1COMPLETED
Alcohol Inhibits Drug Metabolism by Carboxylesterases PHASE1COMPLETED
Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer PHASE1COMPLETED
Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors PHASE1UNKNOWN
A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease PHASE1COMPLETED
Drug-Drug Interaction (DDI) Study in Healthy Volunteers PHASE1COMPLETED
Cocktail Approach for Cytochrome P450 and P-glycoprotein Activity Assessment Using Dried Blood Spot PHASE1COMPLETED
A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers PHASE1COMPLETED
Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease PHASE1ACTIVE_NOT_RECRUITING
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer nanCOMPLETED
The Study of Warfarin Maintenance Dose in Chinese Patients nanUNKNOWN
Connecting Breath and Mind for CYP With Long COVID nanUNKNOWN
Effects of Genotype on CYP2C9 Drug Interactions nanCOMPLETED
PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia nanNOT_YET_RECRUITING
Cytochrome P450 2D6 (CYP 450 2D6) Genotype and Flecainide Efficacy nanUNKNOWN
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages nanCOMPLETED
Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics nanCOMPLETED
Pharmacogenomic Profiling of Pediatric Patients nanCOMPLETED
Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients nanCOMPLETED
Cyclophosphamide in Lupus Nephritis nanUNKNOWN
Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis nanCOMPLETED
Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant Recipients nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CYP2F1 binder may also engage these)

ProteinNameSimilarity
Q8WNE1 — 0.997 Q8WNE1 →
O18809 — 0.993 O18809 →
P00176 — 0.990 P00176 →
P04167 — 0.987 P04167 →
P12791 — 0.986 P12791 →
P12789 — 0.986 P12789 →
CYP2B6 Cytochrome P450 2B6 0.985 landscape →
P00178 — 0.985 P00178 →
O35293 — 0.982 O35293 →
P33267 — 0.981 P33267 →
O55071 — 0.980 O55071 →
P24461 — 0.979 P24461 →
P24460 — 0.977 P24460 →
Q64583 — 0.975 Q64583 →
O93297 — 0.971 O93297 →
Q92090 — 0.970 Q92090 →
P12790 — 0.969 P12790 →
P10610 — 0.969 P10610 →
O93299 — 0.968 O93299 →
Q05556 — 0.968 Q05556 →
Q05555 — 0.968 Q05555 →
CYP2A13 Cytochrome P450 2A13 0.966 landscape →
CYP2A7 Cytochrome P450 2A7 (EC 1.14.14.1) (CYPIIA7) 0.965 landscape →
P33272 — 0.962 P33272 →
CYP2S1 Cytochrome P450 2S1 (EC 1.14.14.-) (CYPIIS1) 0.962 landscape →
CYP2A6 Cytochrome P450 2A6 0.960 landscape →
P15123 — 0.960 P15123 →
Q9DBX6 — 0.959 Q9DBX6 →
E9Q5K4 — 0.958 E9Q5K4 →
P33264 — 0.958 P33264 →